Italia markets closed

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
33,40-4,76 (-12,48%)
Alla chiusura: 04:25PM BST

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240 631 3200
https://www.emergentbiosolutions.com

Settore/i
Settore
Impiegati a tempo pieno2.416

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Robert G. Kramer Sr.CEO, Pres & Exec. Director1,93M7,6M1957
Mr. Richard S. LindahlExec. VP, CFO & Treasurer858,61kN/D1964
Mr. Adam R. HaveyExec. VP & COO843,1k2,18M1971
Mr. Atul SaranExec. VP & Chief Strategy and Devel. Officer820,66kN/D1973
Mr. Robert G. BurrowsVP of Investor RelationsN/DN/DN/D
Ms. Jennifer L. FoxExec. VP of External Affairs, Gen. Counsel & Corp. Sec.N/DN/DN/D
Ms. Coleen GlessnerExec. VP of Global Quality and Ethics & ComplianceN/DN/DN/D
Ms. Lynn KiefferVP of Corp. CommunicationsN/DN/DN/D
Ms. Katherine StreiExec. VP of HR & Chief HR OfficerN/DN/D1962
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Emergent BioSolutions Inc. al 1 maggio 2022 è 5. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.